The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a ...

A few years ago, the advent of technology known as CRISPR was a major breakthrough in the scientific world. Developed from a ...

Introduction: The DNA of a Biotech BoomThe global plasmid DNA manufacturing market is entering a transformative era, driven ...

Researchers harness the power of the world’s most advanced supercomputers to simulate the inner workings of cellular ...

However, therapeutic agents can be delivered directly to the ... and the organ recipient are monozygotic twins, the chromosomal DNA sequence of the donor will be different from that of the recipient.

In addition to its role as a single tumor-killing agent, PAT-DX1 sensitizes cancer cells to other DNA-damaging treatments, enhancing the efficacy of radiation therapy and some chemotherapies.

Applied DNA Sciences (APDN) announced that Applied DNA Clinical Labs is repositioning its TR8 PGx pharmacogenomics testing service to offer ...

Despite the higher levels of DNA damage in polyploid cells, they showed greater resistance to cisplatin than diploid cells.

This discovery, along with the identification of other nitrogenous bases, laid the foundation for our understanding of DNA and RNA structure ... Lamivudine (3TC): A cytosine analog used as an ...

Chemical biology: development of novel molecular probes for DNA sequencing analysis and disease gene discovery Medicinal chemistry: development of new imaging and therapeutic agents towards cancer and ...

The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...